Invivyd Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Rising revenue is outweighed by surging costs and deepening losses at Invivyd.
What the company is saying
Invivyd emphasizes an 18% year-over-year increase in PEMGARDA net product revenue to $15.4 million for Q3 2026, attributing growth primarily to increased patient demand. The company highlights positive topline results from the LIBERTY Phase 3 trial for VYD2311, claiming superior safety and tolerability versus mRNA COVID vaccines, though without disclosing quantitative efficacy data. Management frames the DECLARATION Phase 3 trial as the next regulatory milestone, with interim data and a Biologics License Application submission to the FDA under the Accelerated Approval Program expected imminently. Invivyd also notes the initiation of the FLINTLOCK Phase 2 trial for Long COVID and COVID vaccine injury, and the presentation of a new measles antibody candidate, VMS063, with plans for clinical development in 2027. The company acknowledges that PEMGARDA’s Emergency Use Authorization will terminate in mid-2027 and that it is in active dialogue with the FDA about next steps. Leadership changes are presented as strengthening the board, with Marc Elia appointed CEO and Ajay Royan named Lead Independent Director.
What the data suggests
PEMGARDA net product revenue rose to $15.4 million in Q3 2026 from $13.1 million in Q3 2025, an 18% increase, but this was overshadowed by a sharp rise in expenses. R&D costs more than doubled year-over-year to $18.7 million, driven by spending on the DECLARATION and LIBERTY clinical trials, while SG&A expenses also doubled to $30.3 million due to higher personnel and commercial costs. As a result, net loss widened to $33.5 million from $10.5 million, and net loss per share increased to $0.10 from $0.06. Cash and cash equivalents stood at $126.4 million as of September 30, 2026, providing a buffer but not offsetting the deteriorating earnings trajectory. The DECLARATION trial is at the interim analysis stage, with data expected soon, and is planned to enroll approximately 2,400 participants. LIBERTY completed enrollment (210 participants) and reported positive topline results, but without quantitative outcome data. FLINTLOCK has begun enrolling up to 130 participants for Long COVID and vaccine injury. The company is also scaling up production of VMS063 for measles, targeting clinical development in 2027. Overall, while operational progress is evident, the financial trajectory is negative due to costs rising much faster than revenue.
Analysis
The announcement provides detailed financials, including revenue, expenses, and net loss, as well as operational updates on clinical trials. While PEMGARDA revenue grew 18% year-over-year, expenses (R&D and SG&A) more than doubled, resulting in a sharply higher net loss. The company highlights positive topline results from the LIBERTY Phase 3 trial, but does not disclose specific efficacy or immunogenicity data, relying instead on qualitative claims of superiority. Several forward-looking statements concern the DECLARATION trial, BLA submission plans, and scaling up production for a new candidate, but these are not yet realised and lack quantitative support. The capital intensity is high, with significant R&D spend and plans for further development, but immediate earnings impact is negative. The tone is measured, but some clinical claims are presented with more confidence than the disclosed data supports.
Risk flags
- ●Rapidly escalating R&D and SG&A expenses have outpaced revenue growth, resulting in a net loss that more than tripled year-over-year; if this trend continues, the current $126.4 million cash position could erode quickly, raising future funding risk.
- ●The company's clinical and regulatory milestones are highly concentrated in the DECLARATION Phase 3 trial for VYD2311; failure to achieve positive interim or confirmatory results would materially undermine the investment case and future revenue prospects.
- ●PEMGARDA’s Emergency Use Authorization will terminate in June 2027, creating a hard stop for its current revenue stream and increasing pressure on Invivyd to secure new product approvals or alternative revenue sources before that date.
- ●Claims of clinical superiority for VYD2311 are not supported by disclosed quantitative data, introducing uncertainty about the true magnitude of benefit and the likelihood of regulatory or commercial success.
- ●The company is pursuing multiple development programs simultaneously, including VYD2311 for COVID-19 and VMS063 for measles, which increases execution complexity and capital requirements at a time of widening losses.
Bottom line
Invivyd delivered 18% revenue growth for PEMGARDA in Q3 2026, but this was dwarfed by a surge in R&D and SG&A expenses, driving the net loss to $33.5 million and pushing net loss per share to $0.10. The company's future hinges on the DECLARATION Phase 3 trial for VYD2311, with interim data expected imminently and a Biologics License Application submission planned, but no quantitative clinical results have been disclosed to date. PEMGARDA’s revenue stream is set to expire in June 2027, intensifying the need for new approvals or products to fill the gap. Cash reserves remain substantial at $126.4 million, but the pace of cash burn is concerning given the scale of ongoing clinical programs and the absence of profitability. Investors should focus on the upcoming DECLARATION data release and regulatory update as the critical near-term catalyst. The most important takeaway is that Invivyd’s operational progress is real, but its financial trajectory is deteriorating and future value depends on near-term clinical and regulatory outcomes.
Announcement summary
(NASDAQ:IVVD) Invivyd, Inc. announced financial results for the third quarter ended September 30, 2026, and recent business highlights. Marc Elia was appointed Chairman and Chief Executive Officer of Invivyd in September 2026. Ajay Royan, Founder of Mithril Capital and a member of the Board, was appointed as Lead Independent Director, and Ian Sheffield was appointed as an independent director. PEMGARDA net product revenue was $15.4 million for Q3 2026, compared to $13.1 million for Q3 2025, representing an 18% increase driven primarily by increased patient demand. Cash and cash equivalents were $126.4 million as of September 30, 2026. R&D expenses were $18.7 million for Q3 2026, compared to $8.0 million for Q3 2025, primarily due to higher contract research costs associated with the DECLARATION and LIBERTY clinical trials for VYD2311. SG&A expenses were $30.3 million for Q3 2026, compared to $15.0 million for Q3 2025, mainly due to increased personnel, communications, and commercial-related costs. Net loss was $33.5 million for Q3 2026, compared to $10.5 million for Q3 2025. Basic and diluted net loss per share was $0.10 for Q3 2026, compared to $0.06 for Q3 2025. In July 2026, Invivyd received twelve months’ advanced notice of emergency use authorization (EUA) termination for PEMGARDA, with the EUA set to end in mid-2027, and is in dialogue with the U.S. FDA about next steps. The LIBERTY Phase 3 clinical trial for VYD2311 completed enrollment in June 2026 and reported positive topline results in September 2026, with VYD2311 meeting all primary and secondary endpoints and demonstrating safety and tolerability superior to an mRNA-based COVID-19 vaccine. VYD2311 combined with an mRNA-based COVID-19 vaccine showed no interference with vaccine-induced neutralizing titers and added substantially to those titers. The DECLARATION Phase 3 clinical trial for VYD2311 is planned as the basis for a Biologics License Application (BLA) submission to the FDA under the Accelerated Approval Program, with a prespecified interim analysis designed to evaluate serum virus neutralizing antibody titers, pharmacokinetics, immunogenicity, and safety of VYD2311, and interim data expected imminently. DECLARATION will continue as the confirmatory trial, collecting RT-PCR-confirmed symptomatic COVID-19 events, with total enrollment of approximately 2,400 participants. The FLINTLOCK Phase 2 clinical trial for VYD2311 in adults aged 18-65 years with Long COVID or Post-Vaccination Syndrome was initiated in October 2026, with VYD2311 administered in three doses over 90 days. In October 2026, Invivyd presented VMS063, a novel monoclonal antibody candidate for measles, at IDWeek 2026, with preclinical data showing potent in vitro antiviral activity and plans to scale up production toward clinical development in 2027. LIBERTY enrolled approximately 210 participants, and FLINTLOCK enrolled approximately 130 participants. PEMGARDA is authorized for use only when the combined national frequency of variants with substantially reduced susceptibility to PEMGARDA is less than or equal to 90%. The U.S. Department of Health and Human Services announced on June 30, 2026, that the declaration justifying emergency use authorization will terminate effective June 29, 2027.
Disagree with this article?
Ctrl + Enter to submit